Announcements
- Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
- Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)
- Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs
- Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
- Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
- Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
- Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
- Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
More ▼
Key statistics
On Tuesday, Crinetics Pharmaceuticals Inc (6Z4:DUS) closed at 43.80, -9.88% below its 52-week high of 48.60, set on May 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 42.20 |
---|---|
High | 44.20 |
Low | 42.00 |
Bid | 43.20 |
Offer | 43.80 |
Previous close | 41.00 |
Average volume | 0.00 |
---|---|
Shares outstanding | 78.86m |
Free float | 75.72m |
P/E (TTM) | -- |
Market cap | 3.50bn USD |
EPS (TTM) | -3.77 USD |
Data delayed at least 15 minutes, as of Jun 04 2024 18:31 BST.
More ▼